- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 86,740 | 14.06.24 17:35:44 | -1,810 | -2,04% | 0,000 | 0,000 | 88,320 | 88,550 |
|
Regeneron Pharmaceuticals | 881535 | NASDAQ | 1.035,860 | 14.06.24 21:35:53 | +9,310 | +0,91% | 1.035,610 | 1.036,090 | 1.024,300 | 1.026,550 |
